Bayesian Capital Management LP Takes Position in Omnicell, Inc. (NASDAQ:OMCL)

Bayesian Capital Management LP bought a new stake in Omnicell, Inc. (NASDAQ:OMCL) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 13,600 shares of the company’s stock, valued at approximately $398,000.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Texas Permanent School Fund Corp boosted its position in shares of Omnicell by 1.2% in the first quarter. Texas Permanent School Fund Corp now owns 39,630 shares of the company’s stock worth $1,158,000 after buying an additional 479 shares during the period. ProShare Advisors LLC boosted its position in shares of Omnicell by 7.4% in the first quarter. ProShare Advisors LLC now owns 9,076 shares of the company’s stock worth $265,000 after buying an additional 626 shares during the period. Benjamin Edwards Inc. boosted its position in shares of Omnicell by 36.4% in the first quarter. Benjamin Edwards Inc. now owns 3,253 shares of the company’s stock worth $95,000 after buying an additional 868 shares during the period. Strs Ohio boosted its position in shares of Omnicell by 28.2% in the fourth quarter. Strs Ohio now owns 5,000 shares of the company’s stock worth $188,000 after buying an additional 1,100 shares during the period. Finally, M&T Bank Corp boosted its position in shares of Omnicell by 16.0% in the fourth quarter. M&T Bank Corp now owns 9,570 shares of the company’s stock worth $360,000 after buying an additional 1,321 shares during the period. Institutional investors and hedge funds own 97.70% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently issued reports on OMCL. StockNews.com cut Omnicell from a “buy” rating to a “hold” rating in a research report on Tuesday, July 16th. Benchmark reaffirmed a “buy” rating and issued a $38.00 price target on shares of Omnicell in a research report on Monday, July 15th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $42.20.

Omnicell Trading Down 1.0 %

OMCL traded down $0.30 on Wednesday, hitting $29.09. 6,166 shares of the stock traded hands, compared to its average volume of 509,222. Omnicell, Inc. has a 52 week low of $25.12 and a 52 week high of $66.65. The company has a current ratio of 2.38, a quick ratio of 2.13 and a debt-to-equity ratio of 0.48. The business has a fifty day moving average price of $28.62 and a two-hundred day moving average price of $28.99.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings data on Thursday, May 2nd. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.17. The company had revenue of $246.15 million for the quarter, compared to the consensus estimate of $235.70 million. Omnicell had a positive return on equity of 2.41% and a negative net margin of 1.91%. On average, analysts expect that Omnicell, Inc. will post 0.25 earnings per share for the current year.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.